Collegium Pharmaceutical (NASDAQ:COLL) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report report published on Monday,Benzinga reports. HC Wainwright currently has a $50.00 price target on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also recently commented on the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of COLL opened at $30.56 on Monday. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. The company has a 50-day simple moving average of $30.63 and a 200-day simple moving average of $32.59. Collegium Pharmaceutical has a 52-week low of $27.28 and a 52-week high of $42.29. The company has a market capitalization of $962.21 million, a PE ratio of 13.17 and a beta of 0.99.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Equities research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the transaction, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at approximately $3,937,839.36. This trade represents a 18.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares of the company’s stock, valued at $4,959,032.46. The trade was a 5.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,193 shares of company stock worth $3,243,594. 3.98% of the stock is owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. New Age Alpha Advisors LLC purchased a new position in Collegium Pharmaceutical in the fourth quarter valued at about $40,000. TD Private Client Wealth LLC grew its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV raised its position in shares of Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the period. Virtus Fund Advisers LLC lifted its stake in Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 565 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.